Which has stronger earnings and valuation, BDSX or ITGR?

Integer has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 1.99 -$35.26M -$4.06 N/A Integer $1.85B 1.66 $102.81M $4.01 22.62

Is BDSX or ITGR more profitable?

Integer has a net margin of 7.64% compared to Biodesix's net margin of -33.26%. Integer's return on equity of 12.83% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -33.26% -2,101.40% -35.65% Integer 7.64% 12.83% 6.51%

Which has stronger valuation and earnings, ITGR or ELV?

Elevance Health has higher revenue and earnings than Integer. Elevance Health is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.66 $102.81M $4.01 22.62 Elevance Health $199.13B 0.42 $5.66B $23.51 16.53

Which has preferable valuation & earnings, ITGR or GMED?

Globus Medical has higher revenue and earnings than Integer. Globus Medical is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.66 $102.81M $4.01 22.62 Globus Medical $2.94B 3.64 $537.87M $4.30 18.32

Is ITGR or GMED more profitable?

Globus Medical has a net margin of 18.92% compared to Integer's net margin of 7.64%. Globus Medical's return on equity of 13.46% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% Globus Medical 18.92% 13.46% 11.65%

Which has higher earnings & valuation, ITGR or PODD?

Insulet has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.66 $102.81M $4.01 22.62 Insulet $2.71B 3.69 $247.10M $4.30 33.59

Is ITGR or PODD more profitable?

Insulet has a net margin of 10.44% compared to Integer's net margin of 7.64%. Insulet's return on equity of 26.87% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% Insulet 10.44% 26.87% 12.01%

Integer (ITGR) Competitors

$90.69 +1.19 (+1.33%)

As of 03:49 PM Eastern

Compare

ITGR vs. BDSX, ELV, GMED, BAX, and PODD

Should you buy Integer stock or one of its competitors? MarketBeat compares Integer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Integer include Biodesix (BDSX), Elevance Health (ELV), Globus Medical (GMED), Baxter International (BAX), and Insulet (PODD). These companies are all part of the "medical" sector.

How does Integer compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Integer (NYSE:ITGR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Integer has a net margin of 7.64% compared to Biodesix's net margin of -33.26%. Integer's return on equity of 12.83% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Integer	7.64%	12.83%	6.51%

Biodesix currently has a consensus target price of $26.50, suggesting a potential upside of 56.16%. Integer has a consensus target price of $98.71, suggesting a potential upside of 8.85%. Given Biodesix's stronger consensus rating and higher possible upside, research analysts plainly believe Biodesix is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

21.0% of Biodesix shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Integer has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	1.99	-$35.26M	-$4.06	N/A
Integer	$1.85B	1.66	$102.81M	$4.01	22.62

In the previous week, Biodesix had 11 more articles in the media than Integer. MarketBeat recorded 11 mentions for Biodesix and 0 mentions for Integer. Integer's average media sentiment score of 1.67 beat Biodesix's score of 1.16 indicating that Integer is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodesix	Positive
Integer	Very Positive

Biodesix has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Integer has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

Integer beats Biodesix on 11 of the 16 factors compared between the two stocks.

How does Integer compare to Elevance Health?

Integer (NYSE:ITGR) and Elevance Health (NYSE:ELV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Integer has a net margin of 7.64% compared to Elevance Health's net margin of 2.62%. Elevance Health's return on equity of 15.58% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Elevance Health	2.62%	15.58%	5.57%

Elevance Health has higher revenue and earnings than Integer. Elevance Health is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.66	$102.81M	$4.01	22.62
Elevance Health	$199.13B	0.42	$5.66B	$23.51	16.53

Integer has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Elevance Health has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

In the previous week, Elevance Health had 33 more articles in the media than Integer. MarketBeat recorded 33 mentions for Elevance Health and 0 mentions for Integer. Integer's average media sentiment score of 1.67 beat Elevance Health's score of 1.43 indicating that Integer is being referred to more favorably in the media.

Company	Overall Sentiment
Integer	Very Positive
Elevance Health	Positive

99.3% of Integer shares are owned by institutional investors. Comparatively, 89.2% of Elevance Health shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 0.3% of Elevance Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Integer currently has a consensus target price of $98.71, indicating a potential upside of 8.85%. Elevance Health has a consensus target price of $416.11, indicating a potential upside of 7.07%. Given Integer's higher possible upside, analysts plainly believe Integer is more favorable than Elevance Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Elevance Health	0 Sell rating(s)	9 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.61

Summary

Integer and Elevance Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Integer compare to Globus Medical?

Integer (NYSE:ITGR) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Globus Medical has higher revenue and earnings than Integer. Globus Medical is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.66	$102.81M	$4.01	22.62
Globus Medical	$2.94B	3.64	$537.87M	$4.30	18.32

Globus Medical has a net margin of 18.92% compared to Integer's net margin of 7.64%. Globus Medical's return on equity of 13.46% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Globus Medical	18.92%	13.46%	11.65%

99.3% of Integer shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Integer currently has a consensus price target of $98.71, suggesting a potential upside of 8.85%. Globus Medical has a consensus price target of $105.00, suggesting a potential upside of 33.29%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Globus Medical	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.87

Integer has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Globus Medical had 10 more articles in the media than Integer. MarketBeat recorded 10 mentions for Globus Medical and 0 mentions for Integer. Integer's average media sentiment score of 1.67 beat Globus Medical's score of 1.01 indicating that Integer is being referred to more favorably in the media.

Company	Overall Sentiment
Integer	Very Positive
Globus Medical	Positive

Summary

Globus Medical beats Integer on 14 of the 17 factors compared between the two stocks.

How does Integer compare to Baxter International?

Integer (NYSE:ITGR) and Baxter International (NYSE:BAX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Integer has a net margin of 7.64% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Baxter International	-9.70%	16.15%	5.24%

Integer has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Integer currently has a consensus target price of $98.71, suggesting a potential upside of 8.85%. Baxter International has a consensus target price of $19.73, suggesting a potential downside of 1.25%. Given Integer's stronger consensus rating and higher possible upside, analysts plainly believe Integer is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Baxter International	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, Baxter International had 6 more articles in the media than Integer. MarketBeat recorded 6 mentions for Baxter International and 0 mentions for Integer. Integer's average media sentiment score of 1.67 beat Baxter International's score of 0.44 indicating that Integer is being referred to more favorably in the media.

Company	Overall Sentiment
Integer	Very Positive
Baxter International	Neutral

99.3% of Integer shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Integer has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.66	$102.81M	$4.01	22.62
Baxter International	$11.32B	0.91	-$957M	-$2.13	N/A

Summary

Integer beats Baxter International on 13 of the 16 factors compared between the two stocks.

How does Integer compare to Insulet?

Integer (NYSE:ITGR) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

99.3% of Integer shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Integer presently has a consensus target price of $98.71, indicating a potential upside of 8.85%. Insulet has a consensus target price of $240.78, indicating a potential upside of 66.72%. Given Insulet's stronger consensus rating and higher possible upside, analysts plainly believe Insulet is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Insulet	1 Sell rating(s)	5 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.74

Integer has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Insulet has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Insulet has a net margin of 10.44% compared to Integer's net margin of 7.64%. Insulet's return on equity of 26.87% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
Insulet	10.44%	26.87%	12.01%

Insulet has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.66	$102.81M	$4.01	22.62
Insulet	$2.71B	3.69	$247.10M	$4.30	33.59

In the previous week, Insulet had 10 more articles in the media than Integer. MarketBeat recorded 10 mentions for Insulet and 0 mentions for Integer. Integer's average media sentiment score of 1.67 beat Insulet's score of 1.09 indicating that Integer is being referred to more favorably in the media.

Company	Overall Sentiment
Integer	Very Positive
Insulet	Positive

Summary

Insulet beats Integer on 13 of the 16 factors compared between the two stocks.

Get Integer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITGR vs. The Competition

Export

Metric	Integer	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$3.08B	$6.97B	$6.41B	$23.18B
Dividend Yield	N/A	1.21%	2.67%	4.07%
P/E Ratio	22.62	47.71	24.46	31.54
Price / Sales	1.66	86.20	555.41	103.35
Price / Cash	8.81	25.19	43.94	24.31
Price / Book	1.82	7.16	10.74	4.66
Net Income	$102.81M	$159.20M	$3.57B	$1.08B
7 Day Performance	-1.66%	-0.66%	0.49%	-0.31%
1 Month Performance	0.66%	5.17%	3.48%	2.12%
1 Year Performance	-23.70%	5.39%	28.10%	24.39%

Integer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITGR Integer	2.3792 of 5 stars	$90.69 +1.3%	$98.71 +8.8%	-24.7%	$3.08B	$1.85B	22.62	11,000
BDSX Biodesix	3.8637 of 5 stars	$15.60 +3.6%	$24.00 +53.8%	+167.5%	$155.96M	$88.50M	N/A	220	Trending News Analyst Forecast Analyst Revision Gap Up
ELV Elevance Health	4.5021 of 5 stars	$401.19 -0.7%	$416.11 +3.7%	+4.5%	$87.75B	$199.13B	17.06	97,100	News Coverage Positive News
GMED Globus Medical	4.6953 of 5 stars	$77.25 -3.9%	$105.00 +35.9%	+29.5%	$10.91B	$2.94B	17.97	6,000	Analyst Forecast
BAX Baxter International	1.1988 of 5 stars	$20.80 -0.3%	$19.73 -5.1%	-35.1%	$10.77B	$11.24B	N/A	37,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ITGR) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integer (ITGR) Competitors

ITGR vs. BDSX, ELV, GMED, BAX, and PODD

How does Integer compare to Biodesix?

Summary

How does Integer compare to Elevance Health?

Summary

How does Integer compare to Globus Medical?

Summary

How does Integer compare to Baxter International?

Summary

How does Integer compare to Insulet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITGR vs. The Competition

Integer Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Integer (ITGR) Competitors

ITGR vs. BDSX, ELV, GMED, BAX, and PODD

How does Integer compare to Biodesix?

Is BDSX or ITGR more profitable?

Do analysts rate BDSX or ITGR?

Do institutionals & insiders believe in BDSX or ITGR?

Which has stronger earnings and valuation, BDSX or ITGR?

Does the media prefer BDSX or ITGR?

Which has more volatility and risk, BDSX or ITGR?

Summary

How does Integer compare to Elevance Health?

Is ITGR or ELV more profitable?

Which has stronger valuation and earnings, ITGR or ELV?

Which has more volatility and risk, ITGR or ELV?

Does the media refer more to ITGR or ELV?

Do insiders and institutionals have more ownership in ITGR or ELV?

Do analysts prefer ITGR or ELV?

Summary

How does Integer compare to Globus Medical?

Which has preferable valuation & earnings, ITGR or GMED?

Is ITGR or GMED more profitable?

Do institutionals & insiders hold more shares of ITGR or GMED?

Do analysts prefer ITGR or GMED?

Which has more risk & volatility, ITGR or GMED?

Does the media favor ITGR or GMED?

Summary

How does Integer compare to Baxter International?

Is ITGR or BAX more profitable?

Which has more volatility and risk, ITGR or BAX?

Do analysts rate ITGR or BAX?

Does the media refer more to ITGR or BAX?

Do insiders & institutionals hold more shares of ITGR or BAX?

Which has better valuation & earnings, ITGR or BAX?

Summary

How does Integer compare to Insulet?

Do institutionals and insiders believe in ITGR or PODD?

Do analysts recommend ITGR or PODD?

Which has more volatility and risk, ITGR or PODD?

Is ITGR or PODD more profitable?

Which has higher earnings & valuation, ITGR or PODD?

Does the media refer more to ITGR or PODD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITGR vs. The Competition

Integer Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools